-Reuters
Goldman Sachs Initiates Coverage On CinCor Pharma with Buy Rating, Announces Price Target of $67
Goldman Sachs analyst Madhu Kumar initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Buy rating and announces Price Target of $67.